Follistatin Side Effects: What Studies Report

Where follistatin research actually sits

Follistatin is a secreted glycoprotein best known for binding and neutralising members of the TGF-β superfamily, including activin A and myostatin. Because myostatin restrains skeletal-muscle growth, follistatin has been investigated as a way to increase muscle mass, and a gene-delivery study in nonhuman primates reported that follistatin gene delivery enhanced muscle growth and strength in the treated animals (PMID 20368179). That line of work is the reason the compound is discussed at all outside of endocrinology laboratories.

The practical consequence for side-effect questions is that the human literature and the interventional literature barely overlap. In people, follistatin appears mostly as something measured, not something administered: researchers reported that serum follistatin was increased in thyroid cancer and associated with adverse tumour characteristics in humans (PMID 33493282), and endocrine reviews of relative energy deficiency in sport have catalogued how activin–follistatin axis signalling sits within broader hormonal disturbance in athletes (PMID 38488566). Neither type of paper generates adverse-event data, because no product was given.

Human Safety Data on Follistatin: What Studies Report

The honest summary is an absence. No published controlled trial in the verified literature reviewed here administered follistatin protein or follistatin gene therapy to healthy adults and reported a tabulated adverse-event profile. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance examined this category directly and characterised the safety and efficacy evidence for unapproved agents used for performance purposes as limited (PMID 41966639). That review is the clearest available statement that the safety record for this class is incomplete rather than reassuring.

An absence of reported side effects is not the same as an absence of side effects. Adverse events are only counted when a monitored trial exists to count them. Where no such trial has been published, the literature can describe biological plausibility and animal findings, but it cannot describe human tolerability, dose-limiting toxicity, immunogenicity or long-term outcomes.

What the evidence base looks like at a glance

Animal Gene-Transfer Findings: What Studies Report

The most cited interventional work remains the primate gene-delivery experiment, in which the study reported that follistatin gene delivery enhanced muscle growth and strength in nonhuman primates (PMID 20368179). Findings of that kind establish that the pathway can be manipulated in a large mammal; they do not establish that the same manipulation is tolerable in humans, at what exposure, or for how long.

Gene-transfer approaches also carry questions that belong to the delivery system rather than to follistatin itself. A 2024 study of proteolipid vehicles reported safe and effective in vivo delivery of DNA and RNA in the models tested (PMID 39260374), which illustrates how much of the safety conversation around gene-based muscle interventions concerns vectors, biodistribution and durability of expression. When expression is not switchable, the exposure cannot be stopped in the way an injected drug can be stopped — a structural difference that separates gene-delivery work from conventional peptide pharmacology.

Related Myostatin-Pathway Agents in People: What Studies Report

Because follistatin itself has not been taken through published human trials, the nearest human read-outs come from other agents that act on the same pathway. In healthy volunteers, the study of locally acting ACE-083 — an activin-pathway ligand trap given by intramuscular injection — reported increased volume of the injected muscle (PMID 29486514). That trial demonstrated that local pathway inhibition can change human muscle morphology under monitored conditions.

Findings from a different molecule, a different route and a locally restricted design do not transfer automatically to systemic follistatin exposure. The review of peptide therapies used for musculoskeletal injury and athletic performance made the general point that extrapolating from approved, trial-tested agents to unapproved ones is where safety assumptions tend to break down (PMID 41966639).

Signals Outside Muscle: What Studies Report

Follistatin is not muscle-specific. It participates in reproductive, hepatic, metabolic and inflammatory signalling, which is why researchers examining non-muscle tissues have found the protein tracking with disease states. In thyroid cancer, researchers reported that serum follistatin was increased and associated with adverse tumour characteristics (PMID 33493282). That association was observational: elevated follistatin was measured alongside disease, and the study design did not establish that follistatin caused tumour behaviour or that raising follistatin would reproduce it.

Endocrine reviews have placed the activin–follistatin system inside wider hormonal networks, with the 2024 review of relative energy deficiency in sport describing how endocrine manifestations in energy-deficient athletes span reproductive, bone and metabolic axes (PMID 38488566). Muscle-level biology is similarly networked: a 2020 study reported that metabolic reprogramming of fibro/adipogenic progenitors facilitated muscle regeneration in its model system (PMID 32019766), and an earlier review of frailty, sarcopenia and hormones described how multiple hormonal systems converge on age-related muscle loss (PMID 23702408). The recurring theme across those papers is that a factor with roles in several tissues is difficult to modulate in one tissue alone, and the unapproved-peptide review flagged exactly this kind of off-target uncertainty as unresolved for performance-directed agents (PMID 41966639).

Follistatin Dosing: What the Literature Describes

There is no established human dosing regimen for follistatin in the literature reviewed here. The primate work used gene delivery rather than a repeated protein dose, and the study reported muscle growth and strength outcomes from that delivery approach (PMID 20368179). Gene delivery does not translate into a milligram-per-week schedule, because the exposure is generated by transduced tissue rather than by administered quantity.

The human trial of a related pathway agent used local intramuscular injection into a target muscle and reported increased muscle volume there (PMID 29486514), which is a fundamentally different administration concept from systemic follistatin. Where dosing appears in discussions of unapproved performance peptides, the 2026 review noted that regimens in circulation are frequently unsupported by trial data (PMID 41966639). This page does not restate numbers that the cited papers do not contain.

Endogenous follistatin and exercise

The better-characterised human literature concerns follistatin as an exercise-responsive protein. A randomised controlled trial of 16 weeks of resistance training in older adult women with sarcopenia measured muscle quality and muscle growth factors and reported changes across those measures with training (PMID 34201810). A systematic review and meta-analysis of randomised controlled trials reported that exercise training–induced changes in exerkine concentrations may be relevant to metabolic control in people with type 2 diabetes (PMID 36351545). Those papers describe the body's own regulation of circulating factors, not administration of a follistatin product.

Why Circulating Follistatin Numbers Are Hard to Interpret

Circulating protein concentrations move with factors unrelated to any intervention. A large-scale population study reported that sleep duration was associated with protein biomarkers of cardiometabolic health (PMID 33751690), and a 2024 study reported that circadian misalignment disrupted biomarkers of cardiovascular disease risk and promoted a hypercoagulable state (PMID 39053917). Sleep, shift work, training status, acute exercise, illness and assay method all influence panels of this kind, which is why single measurements of any secreted factor are weak evidence about what an intervention did.

Regulatory context

No follistatin product has been approved by the United States Food and Drug Administration for muscle growth, athletic performance or anti-ageing use. Material sold to laboratories is typically labelled research use only and is not manufactured, tested or released as a medicine. The 2026 review of peptide therapies in musculoskeletal and athletic settings drew the same distinction between approved products with trial evidence and unapproved agents used outside that framework (PMID 41966639).

What remains unknown

• Human tolerability. No published controlled trial has characterised adverse events for administered follistatin in healthy adults; the peptide-therapy review described evidence for unapproved agents as limited (PMID 41966639).
• Non-muscle effects. Human data link elevated follistatin to disease states rather than to exposure, as in the report of increased serum follistatin in thyroid cancer (PMID 33493282).
• Durability and reversibility. The primate evidence came from gene delivery, and the study reported growth and strength outcomes from that approach rather than from a discontinuable dose (PMID 20368179).
• Delivery-system risk. Vector biology carries its own safety questions, as work on proteolipid vehicles for DNA and RNA delivery illustrated (PMID 39260374).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or symptom. It summarises what the cited publications reported and does not describe how any substance should be used.

References

• Follistatin gene delivery enhances muscle growth and strength in nonhuman primates (Science Translational Medicine, 2009)
• Locally acting ACE-083 increases muscle volume in healthy volunteers (Muscle & Nerve, 2018)
• Serum Follistatin Is Increased in Thyroid Cancer and Is Associated With Adverse Tumor Characteristics in Humans (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles (Cell, 2024)
• Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments (Endocrine Reviews, 2024)
• Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial (International Journal of Environmental Research and Public Health, 2021)
• Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials (Journal of Sport and Health Science, 2023)
• Sleep duration is associated with protein biomarkers for cardiometabolic health: A large-scale population study (Journal of Sleep Research, 2021)
• Circadian misalignment disrupts biomarkers of cardiovascular disease risk and promotes a hypercoagulable state (The European Journal of Neuroscience, 2024)
• Metabolic reprogramming of fibro/adipogenic progenitors facilitates muscle regeneration (Life Science Alliance, 2020)
• Frailty, sarcopenia, and hormones (Endocrinology and Metabolism Clinics of North America, 2013)